Five Promising Bio & Healthcare Startups from Gyeonggi Province Join Boston Investment Readiness Program

Five promising bio and healthcare startups based in Gyeonggi Province will participate in an investment readiness program in Boston, USA. Genexis Co., Ltd., a bio-healthcare–focused accelerator, announced that it will operate the “Boston On-Site Program” from September 14 to 20.

The program is part of Genexis’s “2025 U.S. Bio Investment Readiness Program.” It will feature startups that were selected as outstanding companies during a mock demo day and evaluation held on August 21, with participation from domestic and global venture capitalists (VCs) and bio-industry experts.

The five selected startups are DeepSynBio, RadaHeim, Laon Medi, Villex, and ExoSystems. Each company possesses innovative technologies and solutions in the bio and healthcare sector and will explore opportunities for securing global investment.

• DeepSynBio is developing non-invasive therapeutic devices for major brain diseases such as Alzheimer’s disease, mild cognitive impairment, and idiopathic normal-pressure hydrocephalus.
• RadaHeim supports drug development and precision medicine research with an automated, large-scale organoid production platform as an alternative to animal testing.
• Laon Medi is a digital dentistry startup providing AI-powered dental imaging diagnostics and orthodontic treatment-planning solutions.
• Villex is advancing clinical development and technology transfer based on the world’s first drug formulation technology using bilirubin.
• ExoSystems develops solutions for neuromuscular health enhancement through AI-driven digital biomarkers and personalized therapeutic technologies.

In Boston, the program will revolve around RESI Boston 2025, including meetings with global investors, visits to relevant institutions, and engagement with multinational pharmaceutical companies. At RESI Boston 2025, the startups will take part in the Innovator’s Pitch Challenge (IPC), 1:1 partnering meetings, and exhibition booth operations, focusing on securing tangible investment opportunities.

However, the path to attracting overseas investment poses challenges such as local regulatory hurdles, market fit, and commercialization feasibility. The participating companies will need to advance their global commercialization strategies while pursuing both investor engagement and technology validation.

The experiences and investment opportunities gained by Korean bio startups in Boston are expected to serve as an important reference point for the growth of the domestic venture ecosystem.